Superworth

Cencora price to free cash flow COR

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Nov 3, 2026
15.9×
10-year median
13.9×
Against its 10-year history
70th
percentile: 0 is its lowest day, 100 its highest
10-year range
5.8× to 62.1×
Peer median
17.0×

Cencora's price to free cash flow is 15.9× as of Nov 3, 2026.

That is above its ten-year median of 13.9×, higher than on 70% of days in the last ten years.

Over that time it ranged from 5.8× in Nov 2016 to 62.1× in Nov 2025.

The median for 3 medical distribution stocks of a similar size is 17.0×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far15.9×14.4×38.9×
202520.6×14.8×62.1×
202414.6×11.3×22.4×
202311.9×11.6×16.4×
202215.4×10.3×16.3×
202112.4×8.0×19.6×
202010.9×8.5×17.7×
20198.6×7.2×15.7×
201814.6×9.8×30.4×
201719.3×6.7×19.6×
20166.3×4.4×7.4×
20155.8×5.5×17.3×
201416.7×16.6×280×
2013276×90.1×280×
201288.3×60.8×109×
201196.1×81.8×130×
2010102×90.6×124×

Against its peers

Companies in Medical - Distribution nearest Cencora's size, closest first, today.

CompanyPrice to free cash flow
CORCencora15.9×
CAHCardinal Health13.1×
MCKMcKesson18.2×
HSICHenry Schein17.0×
Peer median17.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Cencora

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.